Display options
Cite
Rutten MJ, Sonke GS, Westermann AM, et al. Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer. Obstet Gynecol Int. 2015;2015:464123doi: 10.1155/2015/464123.
Rutten, M. J., Sonke, G. S., Westermann, A. M., van Driel, W. J., Trum, J. W., Kenter, G. G., & Buist, M. R. (2015). Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer. Obstetrics and gynecology international, 2015464123. https://doi.org/10.1155/2015/464123
Rutten, Marianne J, et al. "Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer." Obstetrics and gynecology international vol. 2015 (2015): 464123. doi: https://doi.org/10.1155/2015/464123
Rutten MJ, Sonke GS, Westermann AM, van Driel WJ, Trum JW, Kenter GG, Buist MR. Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer. Obstet Gynecol Int. 2015;2015:464123. doi: 10.1155/2015/464123. Epub 2015 May 27. PMID: 26106418; PMCID: PMC4461774.
Copy Download .nbib Format: NLM
Share it on

Obstet Gynecol Int. 2015;2015:464123. doi: 10.1155/2015/464123. Epub 2015 May 27.

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer.

Obstetrics and gynecology international

Marianne J Rutten, Gabe S Sonke, Anneke M Westermann, Willemien J van Driel, Johannes W Trum, Gemma G Kenter, Marrije R Buist

Affiliations

  1. Centre for Gynaecologic Oncology Amsterdam, Academic Medical Centre, Amsterdam, Netherlands.
  2. Department of Medical Oncology, Netherlands Cancer Institute, P.O. Box 22700, 1100 DE Amsterdam, Netherlands.
  3. Department of Medical Oncology, Academic Medical Centre, Amsterdam, Netherlands.
  4. Centre for Gynaecologic Oncology Amsterdam, Netherlands Cancer Institute, Netherlands.
  5. Centre for Gynaecologic Oncology Amsterdam, Netherlands Cancer Institute, Netherlands ; Centre for Gynaecologic Oncology Amsterdam, Free University Medical Centre, Amsterdam, Netherlands.

PMID: 26106418 PMCID: PMC4461774 DOI: 10.1155/2015/464123

Abstract

Although complete debulking surgery for epithelial ovarian cancer (EOC) is more often achieved with interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT), randomized evidence shows no long-term survival benefit compared to complete primary debulking surgery (PDS). We performed an observational cohort study of patients treated with debulking surgery for advanced EOC to evaluate the prognostic value of residual disease after debulking surgery. All patients treated between 1998 and 2010 in three Dutch referral gynaecological oncology centres were included. The prognostic value of residual disease after surgery for disease specific survival was assessed using Cox-regression analyses. In total, 462 patients underwent NACT-IDS and 227 PDS. Macroscopic residual disease after debulking surgery was an independent prognostic factor for survival in both treatment modalities. Yet, residual tumour less than one centimetre at IDS was associated with a survival benefit of five months compared to leaving residual tumour more than one centimetre, whereas this benefit was not seen after PDS. Leaving residual tumour at IDS is a poor prognostic sign as it is after PDS. The specific prognostic value of residual tumour seems to depend on the clinical setting, as minimal instead of gross residual tumour is associated with improved survival after IDS, but not after PDS.

References

  1. Gynecol Oncol. 2013 Apr;129(1):63-8 - PubMed
  2. Int J Gynecol Cancer. 2010 Nov;20(8):1331-40 - PubMed
  3. J Clin Pathol. 2002 Jan;55(1):27-31 - PubMed
  4. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD007565 - PubMed
  5. Cancer. 2009 Mar 15;115(6):1234-44 - PubMed
  6. Gynecol Oncol. 2013 Jan;128(1):6-11 - PubMed
  7. Cochrane Database Syst Rev. 2014 Feb 21;(2):CD009786 - PubMed
  8. Dan Med J. 2012 Aug;59(8):A4477 - PubMed
  9. Gynecol Oncol. 1998 May;69(2):103-8 - PubMed
  10. N Engl J Med. 2010 Sep 2;363(10):943-53 - PubMed
  11. Ann Surg Oncol. 2012 Dec;19(13):4059-67 - PubMed
  12. Gynecol Oncol. 2012 Jan;124(1):10-4 - PubMed
  13. J Clin Pathol. 2008 May;61(5):652-7 - PubMed
  14. BMC Cancer. 2012 Jan 20;12:31 - PubMed
  15. Int J Gynecol Cancer. 2012 Mar;22(3):380-5 - PubMed
  16. Lancet. 2011 Jan 8;377(9760):127-38 - PubMed
  17. Eur J Cancer. 2012 Sep;48(14):2146-54 - PubMed
  18. Int J Gynecol Cancer. 2011 Dec;21(9):1698-703 - PubMed
  19. Transl Oncol. 2012 Dec;5(6):469-74 - PubMed
  20. Gynecol Oncol. 2013 Feb;128(2):229-32 - PubMed
  21. Int J Gynecol Cancer. 2012 Oct;22(8):1337-43 - PubMed

Publication Types